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Abstract: The aim of this study was to evaluate the ability of Neutrophil Gelatinase-Associated
Lipocalin (NGAL) to predict clinically relevant worsening renal function (WRF) in acute heart
failure (AHF). Plasma NGAL and serum creatinine changes during the first 4 days of admission
were investigated in 1447 patients hospitalized for AHF and enrolled in the Placebo-Controlled
Randomized Study of the Selective A1Adenosine Receptor Antagonist Rolofylline for Patients
Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment
Effect on Congestion and Renal Function (PROTECT) study. WRF was defined as serum creatinine
rise ≥ 0.3 mg/dL through day 4. Biomarker patterns were described using linear mixed models.
WRF developed in 325 patients (22%). Plasma NGAL did not rise earlier than creatinine in patients
with WRF. After multivariable adjustment, baseline plasma NGAL, but not creatinine, predicted
WRF. AUCs for WRF prediction were modest (<0.60) for all models. NGAL did not independently
predict death or rehospitalization (p = n.s.). Patients with WRF and high baseline plasma NGAL
had a greater risk of death, and renal or cardiovascular rehospitalization by 60 days than patients
with WRF and a low baseline plasma NGAL (p for interaction = 0.024). A rise in plasma NGAL after
baseline was associated with a worse outcome in patients with WRF, but not in patients without
WRF (p = 0.007). On the basis of these results, plasma NGAL does not provide additional, clinically
relevant information about the occurrence of WRF in patients with AHF.
Keywords: heart failure; Neutrophil Gelatinase-Associated Lipocalin; NGAL; creatinine; worsening
renal function; acute heart failure
1. Introduction
Worsening renal function (WRF) during hospitalization for acute heart failure (AHF) is associated
with poorer outcome. However, some studies suggest that transient WRF during treatment for AHF
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may not be harmful, and may even reflect a better therapeutic response [1–3]. We recently showed
that patients with AHF and a good diuretic response had a higher incidence of WRF but better
outcomes [4,5]. The cause of WRF appears to be an important factor for determining risk related
to WRF. Early identification of patients at risk of WRF, as well as a robust definition and better
understanding of its cause and consequences, may improve risk stratification. Novel biomarkers may
play a role in achieving this goal.
Neutrophil Gelatinase Associated Lipocalin (NGAL), a 25 kDa member of the Lipocalin family
expressed by the renal tubular epithelium, is released into both urine and blood in response to
tubular injury. Higher plasma NGAL has been associated with poorer clinical outcomes in AHF [6–8].
A number of small studies showed conflicting findings on the potential value of plasma NGAL as
an early marker of WRF [6,9–15]. For instance, in 207 patients with AHF, neither serum creatinine
nor NGAL was able to accurately predict WRF [10]. In sharp contrast, in another study in 119 AHF
patients, NGAL (below a certain cutoff value) had a 100% negative predictive value for the prediction
of WRF [13]. A recent study evaluating NGAL as a predictor of acute kidney injury (AKI) showed
similar results for NGAL, compared with serum creatinine, in the ability to predict AKI [16]. In the
present study, we aimed to establish the value of plasma NGAL as an early predictor of WRF, and as a
discriminator between WRF with a good and a poor prognosis.
2. Results
Patient characteristics for patients with and without WRF, stratified by survival, are presented
in Table 1. Patients who developed WRF during the first four days (n = 325; 22%) had a higher Left
Ventricular Ejection Fraction (LVEF), higher systolic blood pressure, less edema, worse baseline renal
function, higher NGAL levels, lower hemoglobin, and more anemia (all p < 0.05). Profiles for survivors
at 180 days versus patients who died were similar, regardless of whether WRF developed; patients who
died had a lower ejection fraction, lower blood pressure, worse renal function, reflected by higher Blood
Urea Nitrogen (BUN), and plasma concentrations of creatinine and NGAL (all p < 0.05). Tables S1 and
S2 present baseline characteristics, by tertiles, of baseline serum creatinine and plasma NGAL. Higher
levels were associated with more advanced age and more co-morbidity. Plasma concentrations of
NGAL, correlated with serum creatinine (Spearman’s rho 0.58 at baseline and 0.60 at day 4, p < 0.001),
estimated GFR (Spearman’s rho −0.60 at baseline and −0.62 at day 4, p < 0.001) and BUN (Spearman’s
rho 0.52 at baseline and 0.54 at day 4, p < 0.001), and modestly with CRP (Spearman’s rho 0.12 at day 1,
0.13 at day 4, p < 0.001).
2.1. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Worsening Renal Function (WRF)
Figure 1 displays changes in serum creatinine and NGAL during the first week of admission in
patients with and without WRF, adjusted for study treatment. Biomarker changes for alternative WRF
definitions are presented as supplementary Figures S1 and S2, and display similar patterns. Serum
creatinine and plasma NGAL trajectories differed significantly between patients with and without
WRF for all definitions (p for interaction with time <0.001), and rolofylline treatment had no effect
(p = n.s.). Figure 2 shows the relative creatinine and plasma NGAL changes over the first 7 days in
patients with and without WRF. In patients who developed WRF, NGAL levels did not rise significantly
sooner than creatinine levels; both markers increased in parallel over the first 2 days (p for difference
n.s.), with NGAL rising further than creatinine over the course of 7 days, while displaying greater
variability (p < 0.05). Patterns were similar for alternative definitions of WRF (Figures S3 and S4).
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Table 1. Baseline characteristics for patients with and without worsening renal function (WRF), and by vital status, at day 180.
Categories No WRF, Alive No WRF, Dead p * No WRF, Total WRF, Alive WRF, Dead p * WRF, Total p **
(n = 936) (n = 186) (n = 1122) (n = 247) (n = 78) (n = 325)
Demographics
Sex (% Male) 64 (599) 68.3 (127) 0.302 64.7 (726) 69.6 (172) 71.8 (56) 0.825 70.2 (228) 0.079
Age (years) 69.6 ± 11.6 72.4 ± 10.7 0.001 70 ± 11.5 71.1 ± 10.3 71.9 ± 10.7 0.578 71.3 ± 10.4 0.058
BMI (kg/m2) 28.8 ± 6 27.8 ± 5.7 0.032 28.6 ± 6 29.1 ± 5.8 28.3 ± 6 0.311 28.9 ± 5.9 0.516
LVEF (% (n)) 32.7 ± 12.8 28.6 ± 11 0.001 31.9 ± 12.5 36.5 ± 13.9 30.5 ± 13.4 0.021 34.9 ± 14 0.020
Systolic Blood Pressure (mmHg) 125.7 ± 17.3 117.8 ± 17.2 <0.001 124.4 ± 17.6 129.2 ± 16.6 120.1 ± 16.4 <0.001 127 ± 17 0.015
Diastolic Blood Pressure (mmHg) 74.8 ± 11.5 71 ± 10.7 <0.001 74.1 ± 11.5 76.9 ± 12.1 71.2 ± 10.8 <0.001 75.5 ± 12 0.060
Heart Rate (beats/min) 81.6 ± 16.4 80.3 ± 15.1 0.286 81.4 ± 16.2 80.3 ± 14.9 78.8 ± 14.8 0.452 79.9 ± 14.9 0.124
Rolofylline administration (% (n)) 65.2 (610) 69.4 (129) 0.310 65.9 (739) 72.5 (179) 65.4 (51) 0.291 70.8 (230) 0.112
Clinical Profile
Orthopnea (% (n)) 96.6 (896) 94.6 (175) 0.287 96.2 (1071) 95.1 (233) 100 (78) 0.099 96.3 (311) 1.000
Rales (% (n)) 63.5 (594) 61.3 (114) 0.621 63.2 (708) 64.8 (160) 65.4 (51) 1.000 64.9 (211) 0.605
Edema (% (n)) 71.2 (666) 71 (132) 1.000 71.1 (798) 63.6 (157) 60.3 (47) 0.695 62.8 (204) 0.005
Jugular venous pressure (% (n)) 41.2 (344) 49.4 (81) 0.064 42.5 (425) 40.3 (87) 43.7 (31) 0.716 41.1 (118) 0.716
Medical History
Hypertension (% (n)) 80.1 (750) 79 (147) 0.810 79.9 (897) 79.8 (197) 74.4 (58) 0.394 78.5 (255) 0.612
Diabetes Mellitus (% (n)) 44.9 (420) 45.7 (85) 0.899 45 (505) 44.5 (110) 41.6 (32) 0.743 43.8 (142) 0.754
Hypercholesterolemia (% (n)) 45.7 (427) 42.5 (79) 0.472 45.1 (506) 51.4 (127) 48.7 (38) 0.775 50.8 (165) 0.084
Smoking (% (n)) 18.6 (174) 19.5 (36) 0.867 18.8 (210) 14.2 (35) 20.5 (16) 0.250 15.7 (51) 0.247
Ischemic Heart Disease (% (n)) 69.3 (648) 74.6 (138) 0.177 70.2 (786) 69.2 (171) 73.1 (57) 0.613 70.2 (228) 1.000
Myocardial Infarction (% (n)) 49 (458) 54.3 (100) 0.216 49.9 (558) 48.2 (119) 52.6 (41) 0.585 49.2 (160) 0.879
PCI (% (n)) 21.9 (203) 26.8 (49) 0.182 22.7 (252) 22.3 (55) 23.4 (18) 0.962 22.5 (73) 1.000
CABG (% (n)) 18.6 (172) 21.9 (40) 0.349 19.1 (212) 21.9 (54) 25.6 (20) 0.590 22.8 (74) 0.168
Peripheral Vascular Disease (% (n)) 10.2 (95) 15.1 (28) 0.069 11 (123) 11 (27) 14.3 (11) 0.559 11.8 (38) 0.769
Atrial Fibrillation (% (n)) 55.6 (518) 57 (106) 0.797 55.9 (624) 55.1 (136) 50 (39) 0.515 53.8 (175) 0.561
NYHA Class 0.426 0.059 0.578
I–II 16.6 (155) 13.4 (25) 16 (180) 19.8 (49) 10.3 (8) 17.5 (57)
III 44.9 (420) 49.5 (92) 45.6 (512) 45.7 (113) 59 (46) 48.9 (159)
IV 32.8 (307) 31.7 (59) 32.6 (366) 31.6 (78) 26.9 (21) 30.5 (99)
ICD therapy (% (n)) 12.6 (118) 17.2 (32) 0.119 13.4 (150) 12.6 (31) 19.2 (15) 0.197 14.2 (46) 0.790
CRT therapy (% (n)) 7.2 (67) 14 (26) 0.003 8.3 (93) 11.3 (28) 9 (7) 0.706 10.8 (35) 0.205
Stroke (% (n)) 8.3 (78) 9.1 (17) 0.828 8.5 (95) 12.6 (31) 19.2 (15) 0.197 14.2 (46) 0.003
COPD (% (n)) 19.4 (181) 21.6 (40) 0.545 19.7 (221) 18.6 (46) 21.8 (17) 0.650 19.4 (63) 0.953
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Table 1. Cont.
Categories No WRF, Alive No WRF, Dead p * No WRF, Total WRF, Alive WRF, Dead p * WRF, Total p **
(n = 936) (n = 186) (n = 1122) (n = 247) (n = 78) (n = 325)
Prior Medication Use
ACE inhibitors or ARB (% (n)) 76.4 (715) 69.9 (130) 0.074 75.3 (845) 76.5 (189) 71.8 (56) 0.488 75.4 (245) 1.000
Beta blockers (% (n)) 74.7 (699) 75.3 (140) 0.939 74.8 (839) 74.5 (184) 67.9 (53) 0.323 72.9 (237) 0.547
MRA (% (n)) 45.8 (429) 48.4 (90) 0.577 46.3 (519) 47.4 (117) 59 (46) 0.097 50.2 (163) 0.239
Calcium Antagonists (% (n)) 12.7 (119) 8.6 (16) 0.147 12 (135) 21.9 (54) 7.7 (6) 0.008 18.5 (60) 0.004
Nitrates (% (n)) 26.9 (252) 26.9 (50) 1.000 26.9 (302) 27.5 (68) 29.5 (23) 0.849 28 (91) 0.752
Digoxin (% (n)) 31 (290) 31.2 (58) 1.000 31 (348) 32.4 (80) 20.5 (16) 0.063 29.5 (96) 0.660
Laboratory Values
Creatinine (mg/dL) 1.3 (1.1–1.7) 1.5 (1.2–2.1) <0.001 1.3 (1.1–1.7) 1.4 (1.2–1.8) 1.7 (1.3–2) 0.002 1.5 (1.2–1.8) <0.001
eGFR (mL/min/1.73 m2) 52 (39–66) 45 (33–60) <0.001 51 (38–65) 48 (38–62) 40 (32–51) <0.001 46 (37–59) <0.001
NGAL (ng/mL) 78 (50–123) 96 (58–137) 0.008 81 (52–127) 90 (56–142) 131 (72–187) 0.002 93 (58–151) <0.001
Blood Urea Nitrogen (mg/dL) 28 (21–38) 37 (26–51) <0.001 29 (22–40) 28 (23–38) 41 (30–55) <0.001 31 (24–43) 0.029
Sodium (mmol/L) 140 (137–143) 138 (135–141) <0.001 140 (137–142) 141 (138–143) 139 (136–142) 0.010 140 (138–143) 0.063
Potassium (mmol/L) 4.2 (3.9–4.6) 4.3 (3.9–4.8) 0.175 4.2 (3.9–4.6) 4.3 (4–4.7) 4.3 (3.9–4.7) 0.815 4.3 (3.9–4.7) 0.090
Hemoglobin (g/dL) 12.9 ± 2 12.7 ± 1.9 0.216 12.8 ± 2 12.5 ± 1.9 12.3 ± 1.8 0.399 12.5 ± 1.9 0.007
Anemia (% (n)) 38.3 (314) 44.4 (75) 0.169 39.4 (389) 46.6 (102) 49.3 (34) 0.800 47 (136) 0.021
BNP (mg/dL) 1195 (815–2228) 1895 (1172–3300) <0.001 1351 (852–2433) 1073(718–1616)
1749
(1153–2829) 0.006
1190
(779–2078) 0.227
Abbreviations: BMI: Body Mass Index; LVEF: Left Ventricular Ejection Fraction; PCI: Percutaneous Coronary Intervention; CABG: Coronary Artery Bypass Graft; NYHA: New York Heart
Association; ICD: Internal Cardiac Defibrillator; CRT: Cardiac Resynchronization Therapy; COPD: chronic obstructive pulmonary disease; ACE: Angiotensin Converting Enzyme; ARB:
Aldosterone Receptor Blocker; MRA: Mineralocorticoid Receptor Antagonist; eGFR: estimated Glomerular Filtration Rate; BNP: Brain Natriuretic Peptide. Categorical variables are
presented as: % (N). * p value for dead vs. alive, ** p value for WRF vs. No WRF. To convert Creatinine from mg/dL to µmol/L, multiply by 88.4.
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Figure 1. (a) Change in serum creatinine in patients with and without WRF; (b) Change in plasma 
Neutrophil Gelatinase-Associated Lipocalin (NGAL) in patients with and without WRF. Least square 
means, with 95% confidence intervals, WRF: worsening renal function, defined as a creatinine 
increase of ≥0.3 mg/dL by day 4. 
 
Figure 2. Relative changes in serum creatinine and NGAL. Least square means with 95% confidence 
intervals. WRF: worsening renal function, defined as creatinine increase of ≥0.3 mg/dL by day 4. 
Figure 1. (a) Change in serum creatinine in patients with and without WRF; (b) Change in plasma
Neutrophil Gelatinase-Associated Lipocalin (NGAL) in patients with and without WRF. Least square
means, with 95% confidence intervals, WRF: worsening renal function, defined as a creatinine increase
of ≥0.3 mg/dL by day 4.
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In ROC curve analyses, WRF proved difficult to predict well, with modest AUC values. Baseline
and day 2 NGAL and creatinine were similarly predictive of WRF, while a non-diagnostic creatinine
change on day 2 was a much stronger predictor of WRF than NGAL change on day 2 (Table 2).
Table 2. Predictive value of NGAL and Creatinine for WRF.
Baseline Values
WRF definition Creatinine AUC NGAL AUC p *
≥0.3 mg/dL increase 0.571 0.569 0.930
Day 2 Values
WRF definition Creatinine AUC NGAL AUC p *
≥0.3 mg/dL increase 0.617 0.570 0.097
Change on Day 2
WRF definition Creatinine AUC NGAL AUC p *
≥0.3 mg/dL increase 0.718 0.491 <0.001
* p for difference in AUC.
In sensitivity analyses, predictive value for other WRF definitions/cut-offs showed similar
patterns (Tables S3 and S4). Baseline plasma NGAL was independently predictive of WRF in a
multivariable model (Table 3), while serum creatinine was not. NGAL contributed significantly to
improving WRF prediction (AUC 0.648 vs. 0.635 for model with vs. without NGAL, p = 0.002).
In sensitivity analyses, multivariable models for other WRF cut-offs consistently included NGAL,
which significantly improved model discrimination in all models (p < 0.05), but not creatinine. However,
these small improvements are likely not clinically relevant.
Table 3. Multivariable logistic regression for prediction of worsening renal function.
Variables OR (95% CI) χ2 p
Cholesterol (per SD) 1.33 (1.16–1.52) 16.26 <0.001
Hemoglobin (per SD) 0.77 (0.67–0.90) 11.45 0.001
NGAL (per SD) 1.23 (1.08–1.40) 9.79 0.002
History of Stroke 1.89 (1.25–2.83) 9.52 0.002
Male Sex 1.48 (1.10–2.01) 6.55 0.010
Albumin (per SD) 1.19 (1.03–1.38) 5.77 0.016
Rolofylline treatment 1.39 (1.04–1.87) 4.78 0.029
Abbreviations: SD: standard deviation; OR: Odds Ratio.
2.2. NGAL and Clinically Relevant WRF
To investigate the value of NGAL for distinguishing between WRF with good and poor outcomes,
we examined NGAL and creatinine trajectories (Figure 3) in patients who experienced WRF (or not)
who had died, or were alive, after 180 days. Baseline plasma NGAL was higher and rose further
in patients who died compared to survivors, and was higher in patients with WRF, irrespective of
outcome. The pattern was similar when the 60-day endpoint was examined. In mutually adjusted
models, including NGAL and Creatinine, NGAL was a stronger predictor of WRF with a poor outcome,
and improved the model when added to creatinine, showing consistently higher Goodness of Fit
(Table 4).
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Figure 3. (a) Changes in serum Creatinine; and (b) NGAL in patients with and without worsening 
renal function, by vital status, at 180 days. Least square means with 95% confidence intervals. WRF: 
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Figure 3. (a) Changes in serum Creatinine; and (b) NGAL in patients with and without worsening
renal function, by vital status, at 180 days. Least square means with 95% confidence intervals. WRF:
worsening renal function, defined as a creatinine increase of ≥0.3 mg/dL by day 4.
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Table 4. Added value of NGAL on top of creatinine for predicting clinically relevant WRF.
WRF definition MV Model * OR (95% CI) χ2 p-value ** AUC p-value ***
WRF and 180-day mortality ****
≥0.3 mg/dL increase
Creatinine 1.26 (1.02–1.55) 4.81 0.028 0.670 0.021
NGAL 1.25 (1.04–1.48) 6.52 0.011
≥25% & ≥0.3mg/dL increase
Creatinine 1.03 (0.78–1.33) 0.04 0.833 0.637 0.017
NGAL 1.31 (1.06–1.56) 7.53 0.006
WRF and 60-day endpoint ****
≥0.3 mg/dL increase
Creatinine 1.25 (1.03–1.5) 5.36 0.021 0.656 0.001
NGAL 1.32 (1.12–1.55) 11.69 0.001
≥25% & ≥0.3mg/dL increase
Creatinine 1.03 (0.81–1.29) 0.05 0.821 0.633 0.005
NGAL 1.31 (1.09–1.55) 9.57 0.002
* Multivariable logistic model, including both creatinine and NGAL; odds ratios presented per standard deviation;
** Multivariable p value for WRF prediction; *** Likelihood ratio test for added value of adding NGAL to a model
with creatinine alone; **** Prediction of WRF with poor clinical outcome, compared to all other patients.
2.3. NGAL, WRF, and Clinical Outcome
In Cox models, baseline serum creatinine and plasma NGAL were invariably associated with
both 180-day mortality and the 60-day composite (all p < 0.001), although this did not persist following
multivariable adjustment (all p = n.s.). WRF was independently associated with both endpoints
(multivariable HR for 180-day mortality: 1.45, 95% CI 1.12–1.88, p = 0.004; multivariable HR for the
60-day composite: 1.27, 95% CI 1.01–1.59, p = 0.04); sensitivity analyses with absolute creatinine change
and other definitions for WRF showed similar performance (data not shown).
In patients with a rise in serum creatinine, higher baseline plasma NGAL (p for interaction
0.024)—but not higher baseline serum creatinine (p for interaction = 0.464)—posed a significant,
relatively greater risk of reaching the 60-day composite endpoint. Supplementary Figure S5 displays the
multivariable hazard ratios for the 60-day composite endpoint for the continuous interactions between
creatinine change, and baseline values of creatinine or NGAL. The continuous hazard functions for
creatinine change, stratified by either baseline creatinine levels (first panel) or baseline NGAL levels
(second panel), illustrate the interaction between creatinine change and baseline biomarker levels.
Patterns were similar for the 180-day mortality endpoint, but no interactions reached significance.
The clinical value of changes in NGAL, combined with WRF, was examined by comparing clinical
outcomes between patients with and without WRF, and with a similar rise in NGAL on day 4. This
was defined as an increase of ≥1 SD (≥88 ng/mL) in NGAL (n = 83), as the SD for creatinine change by
day 4 was about 0.3 mg/dL, resembling the definition of WRF. The Kaplan-Meier curve is displayed in
Figure 4, showing a significantly increased risk of mortality, only if both markers rose significantly
(p-value for WRF with NGAL increase ≥88 ng/mL versus the other three groups = 0.007). Patients
with ≥1 SD rise in NGAL had significantly higher creatinine at baseline than those who did not (p <
0.05), but similar levels, irrespective of whether WRF developed (1.8 vs. 1.7 mg/dL with vs. without
WRF, p = 0.59). Baseline characteristics in this small subgroup did not differ significantly based on
WRF status.
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3. Discussion
We xamined the value of NGAL for predicting clinically relevant WRF and outcomes in 1447
patients admitted with AHF (to our knowledge, the largest cohort of AHF patients wi available
serial plasma NGAL measurements). WRF was common, occurring in 22% of patients duri g the first
four days of admission. Patients who developed WRF were more likely to have poor renal function
at baseline, although only NGAL levels—but not creatinine—were independently associated with
the development of WRF. We found no indication that plasma NGAL rises earlier than creatinine in
AHF patients who develop WRF; both markers rose in tandem over the first two days of admission.
Although NGAL showed statistically significant incremental value for predicting WRF, no combination
of markers performed particularly well, with AUCs below 0.60. While high levels of both NGAL and
creatinine at baseline were associated with mortality and rehospitalization, neither was independently
predictive after adjustment for clinical covariates.
3.1. Prediction of WRF
NGAL has been identified as a powerful early predictor of WRF in a number of different clinical
settings [17–25], although the data in AHF are conflicting [6,7,10–15,26]. Similarly to Breidthardt et
al. [10], we found modest predictive ability for plasma NGAL, which provided minimal improvement
on top of creatinine for predicting WRF. Our data further confirm findings by the prospective biomarker
study Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic
Heart Failure Study (AKINESIS) that recently showed similar results—NGAL was not a ore sensitive
predictor of AKI in patients dmitted with acute HF [16]. Whereas AKINESIS only assessed evere
and sustained increases in creatinine, mor closely r sembling acute ki ney injury, we evaluated
the much more common used definitions of WRF. Furthermore, our study not only provides data
on inhospital changes in plasma NGAL, but also long term outcomes, whereas in AKINESIS only
inhospital events were evaluated. In the end, considering the poor performance of both markers for
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AKI/WRF prediction in both AKINESIS and the present study, the clinical relevance of the associations
is debatable at best.
One potential issue is the self-fulfilling nature of predicting a rise in creatinine, using creatinine.
Interestingly, we found that baseline NGAL values—but not baseline creatinine values—predicted
WRF in multivariable models. Regardless, the hypothesis that NGAL rises earlier than creatinine
does not hold true in this AHF cohort, as illustrated by the estimated trajectories corrected for study
treatment. There are several potential explanations for the lack of an early rise in plasma NGAL, and
thus the poor prognostic accuracy for WRF in AHF. First, plasma NGAL—in contrast with urinary
NGAL—may not be a particularly appropriate tubular marker; it is strongly related to glomerular
filtration rate, as reflected by its correlation with GFR and creatinine, and also involved in iron
scavenging and immune response, as indicated by the correlation with markers such as CRP and
markers of anemia [27,28]. Shrestha et al noted strong correlations between urinary NGAL and
measures for natriuresis and response to diuretics, while plasma NGAL only correlated well with
GFR, though both predicted WRF [14]. Second, there are multiple mechanisms for WRF in AHF
patients. For example, true AKI (resulting in tubular damage), with substantial and rapid loss
of function and decreased urine output is probably not comparable to the kind of WRF studied
extensively in AHF. In the clinical context of AHF, changes in renal function may be driven more by
hemodynamic and neurohormonal (mal) adaptation and drug effects than the (hypoxic) kidney injury
common in intensive care or post-surgical settings; Dupont et al. showed that despite a relatively high
incidence of AKI, defined based on creatinine increases, tubular injury was relatively uncommon in
a small, prospective study of 141 AHF patients [26]. Third, in contrast with studies in post-surgical
or post-intervention patients [17–19,24,25,29], the timing of renal injury is often unclear in AHF, and
its pre-hospital course may vary significantly, and may include undetected WRF. Pre-admission
worsening congestion and intensification of diuretic therapy may have already triggered progressive
renal impairment in the patients in our study—all of whom had at least a brief history of heart failure.
Fourth, there is ongoing debate regarding the best measure for renal function and injury; a definition
of WRF, based on a more “pure” marker, such as cystatin C or measured GFR, may have yielded very
different results.
However, it is noteworthy that our additional analysis of clinically relevant WRF (that is, WRF
associated with poor clinical outcome) showed patients with WRF (and an adverse outcome had much
higher NGAL levels).
3.2. NGAL, Creatinine and Outcome
Impaired and worsening renal function are established risk markers in heart failure [30]. Data
on the prognostic value of NGAL is mixed, with many [7,8,12,31–34]—but not all [35]—studies
in both chronic and AHF reporting prognostic value, though correction for potential confounders
varies greatly. Givertz et al. previously reported on the prognostic value of various renal markers in
PROTECT, concluding that creatinine change and baseline BUN were strong predictors of outcome [36].
Additionally, our analyses show that NGAL modulates the risk of outcomes associated with creatinine
change, conferring a greater relative risk to patients with higher NGAL levels with a creatinine increase,
but not to patients without. This effect is independent of baseline creatinine. Furthermore, a large
increase in NGAL during admission conferred an additional risk of death (only in patients with WRF).
Thus, while plasma NGAL levels appear to largely reflect GFR (and thus creatinine), they do have some
incremental value for assessing the risk associated with WRF, and could help discriminate between
higher and lower risk WRF.
3.3. Clinical Perspectives
Identifying patients at high risk of developing renal dysfunction and poor outcomes remains
a challenge in AHF. Coupled with a lack of effective therapeutic options, this poses a problem for
clinicians. Biomarkers such as NGAL can be used as diagnostic or prognostic tools, though their
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application requires careful and thorough evaluation. Despite the extensive but conflicting literature
on plasma NGAL, our analyses in this very large group of well-characterized AHF patients, together
with findings from AKINESIS, indicate fairly poor accuracy for predicting WRF.
Plasma NGAL was not independently prognostic for death or rehospitalization. Our findings
suggest elevated baseline NGAL levels, and large increases in NGAL do confer additional risk for
patients who develop WRF (although the clinical relevance of these findings—given the lack of
independent prognostic value for NGAL, the small numbers of patients with NGAL increases, and the
post-hoc nature of our analyses—remains to be established).
3.4. Limitations
Due to the retrospective nature of this study, our results should be considered
hypothesis-generating, and should therefore be interpreted cautiously. Furthermore, NGAL was
measured using frozen samples, which may have affected data quality. No urine was collected, so the
performance of urinary NGAL could not be compared that of plasma NGAL, and may have shown
very different patterns and results.
4. Materials and Methods
4.1. Study Design and Population
This is a post hoc analysis of the Placebo-controlled Randomized Study of the Selective A1
Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Heart Failure and
Volume Overload to Assess Treatment Effect on Congestion and Renal FuncTion (PROTECT) trial, a
randomized, double-blind, placebo-controlled, multi-center study that enrolled 2033 patients admitted
for acute decompensated heart failure, randomized 2:1 to rolofylline, with neutral overall results.
Study design, inclusion, and exclusion criteria and results have been published previously [37–39]. The
trial was approved by all local Ethics Committees and conducted in accordance with the Declaration
of Helsinki (NCT00328692 and NCT00354458). All patients provided written informed consent. Of
the patients who remained hospitalized for at least 4 days (n = 1681), those with available NGAL
and creatinine values at baseline (n = 1470), and at least one follow-up measurement for each marker
during the first 4 days, were included in the analysis, resulting in a study population of 1447 patients.
Patients who had already developed WRF by day 2 (n = 101) were excluded from analyses of the
effects of biomarker levels and changes on day 2.
4.2. Procedures and Definitions
Heart failure signs and symptoms, serum creatinine, and other hematologic and biochemical
markers, were assessed daily from baseline (day 1) until discharge or day 6 and on day 7, as dictated
by study protocol [37]. Plasma NGAL levels were measured in frozen plasma samples collected on the
same days and stored at −80 ◦C. Measurements were performed by Alere Inc. (San Diego, CA, USA)
using sandwich enzyme-linked immunosorbent assays (ELISA) on a microtiter plate. The estimated
glomerular filtration rate (GFR) was calculated using the simplified modification of diet in renal disease
(MDRD) study equation.
4.3. Endpoints
This study examined WRF occurring during the first 4 days of hospitalization, defined as a
creatinine increase of ≥0.3 mg/dL (26.5 µmol/L), at any time between day 1 (baseline) and day 4, or
initiation of hemofiltration as it was defined in the main study. Sensitivity analyses were performed
with other definitions, including absolute creatinine, a relative creatinine increase of≥25%, a combined
increase of ≥0.3 mg/dL and ≥25%, and various cut-offs.
The prognostic value of plasma NGAL for distinguishing between WRF and good vs. poor
prognosis was examined for adjudicated endpoints of 180-day mortality and a composite of 60-day
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death or renal or cardiovascular rehospitalization. WRF with good vs. poor outcome was defined
based on whether patients experienced either of the clinical endpoints.
4.4. Statistical Methods
Continuous data are presented as mean ± SD if normally distributed, or median [interquartile
range] if not. Group comparisons were performed using Student’s t-test, ANOVA, Wilcoxon, or
Kruskall-Wallis tests, as appropriate. Differences between relative changes in biomarkers were assessed
using paired Wilxocon rank sum tests. Correlations between biomarkers were evaluated using
Spearman’s rank correlation. Missing data were assumed to be missing at random, and no imputations
were performed.
Changes in serial biomarker measurements were evaluated using random slope, random intercept
linear mixed-effects models, adjusted for study treatment. A mixed-effects model is a hierarchical
regression model that includes fixed and random (subject-specific) effects, allowing for within-subject
correlation between repeated measurements. Both NGAL and creatinine were log-transformed for
modeling. Model selection was based on combined assessment of likelihood ratio tests of nested
models for selection of random effects, and of Bayesian and Akaike’s information criteria (measures
for model fit, lower is better) for selection of fixed effects, following graphical exploration of the data.
Best fit was obtained using a second order polynomial (quadratic) time transformation for creatinine
and third order polynomial (cubic) time transformation for NGAL, for both fixed and random effects.
Receiver Operator Characteristic (ROC) curve analyses and multivariable logistic regression were
performed to evaluate predictors of WRF, and added value in multivariable models was assessed
using likelihood ratio tests of nested models. Multivariable models were constructed via backward
elimination of candidate covariates with a univariable association at p < 0.1, with a p for retention of
0.05.
Kaplan Meier survival analyses were performed to examine group associations with the mortality
and composite endpoints. Outcomes between groups were compared with log-rank tests. Cox
proportional hazards regression was performed to evaluate univariable and multivariable associations
with 180-day mortality and the 60-day composite, adjusting for covariates from a previously published
prognostic model—age, creatinine, BUN, systolic blood pressure, edema, previous hospitalization for
heart failure, serum albumin, and serum sodium [40]. Multiple fractional polynomials were used to
check for non-linearity in survival analyses. Interactions were investigated graphically. Proportionality
of hazards assumptions were evaluated graphically and tested statistically. A two-tailed p-value of
0.05 was considered statistically significant. All analyses were performed using R: A Language and
Environment for Statistical Computing, version 3.1.0 (R Foundation for Statistical Computing, Vienna,
Austria) and Stata, version 11.2 (College Station, TX, USA).
5. Conclusions
Plasma NGAL was not independently predictive of poor outcome, though serial plasma NGAL
levels provide some additional information for the prediction of clinically significant WRF in patients
with AHF. However, plasma NGAL levels did not rise earlier than creatinine in patients who developed
WRF, and both NGAL and creatinine were similarly modest predictors of WRF.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/18/7/
1470/s1.
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